169 related articles for article (PubMed ID: 33759216)
1. Blood retinal barrier and ocular pharmacokinetics: Considerations for the development of oncology drugs.
Williamson B; Pilla Reddy V
Biopharm Drug Dispos; 2021 Apr; 42(4):128-136. PubMed ID: 33759216
[TBL] [Abstract][Full Text] [Related]
2. Neuro-ophthalmic side effects of molecularly targeted cancer drugs.
Bhatti MT; Salama AKS
Eye (Lond); 2018 Feb; 32(2):287-301. PubMed ID: 29052609
[TBL] [Abstract][Full Text] [Related]
3. Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors.
Infante JR; Camidge DR; Mileshkin LR; Chen EX; Hicks RJ; Rischin D; Fingert H; Pierce KJ; Xu H; Roberts WG; Shreeve SM; Burris HA; Siu LL
J Clin Oncol; 2012 May; 30(13):1527-33. PubMed ID: 22454420
[TBL] [Abstract][Full Text] [Related]
4. Metabolism-related pharmacokinetic drug-drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations.
Teo YL; Ho HK; Chan A
Br J Clin Pharmacol; 2015 Feb; 79(2):241-53. PubMed ID: 25125025
[TBL] [Abstract][Full Text] [Related]
5. Toxicities of Receptor Tyrosine Kinase Inhibitors in Cancer Pharmacotherapy: Management with Clinical Pharmacology.
Fujita KI; Ishida H; Kubota Y; Sasaki Y
Curr Drug Metab; 2017; 18(3):186-198. PubMed ID: 28059038
[TBL] [Abstract][Full Text] [Related]
6. Investigational multitargeted kinase inhibitors in development for head and neck neoplasms.
Sola AM; Johnson DE; Grandis JR
Expert Opin Investig Drugs; 2019 Apr; 28(4):351-363. PubMed ID: 30753792
[TBL] [Abstract][Full Text] [Related]
7. ABC transporters in multi-drug resistance and ADME-Tox of small molecule tyrosine kinase inhibitors.
Deng J; Shao J; Markowitz JS; An G
Pharm Res; 2014 Sep; 31(9):2237-55. PubMed ID: 24842659
[TBL] [Abstract][Full Text] [Related]
8. Metabolism and Distribution of Novel Tumor Targeting Drugs In Vivo.
Wang M; Du Q; Zuo L; Xue P; Lan C; Sun Z
Curr Drug Metab; 2020; 21(13):996-1008. PubMed ID: 33183197
[TBL] [Abstract][Full Text] [Related]
9. Ocular toxicity of targeted therapies.
Renouf DJ; Velazquez-Martin JP; Simpson R; Siu LL; Bedard PL
J Clin Oncol; 2012 Sep; 30(26):3277-86. PubMed ID: 22649132
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic Targets for Therapeutic Drug Monitoring of Small Molecule Kinase Inhibitors in Pediatric Oncology.
Janssen JM; Dorlo TPC; Steeghs N; Beijnen JH; Hanff LM; van Eijkelenburg NKA; van der Lugt J; Zwaan CM; Huitema ADR
Clin Pharmacol Ther; 2020 Sep; 108(3):494-505. PubMed ID: 32022898
[TBL] [Abstract][Full Text] [Related]
11. Ocular adverse events of molecularly targeted agents approved in solid tumours: a systematic review.
Huillard O; Bakalian S; Levy C; Desjardins L; Lumbroso-Le Rouic L; Pop S; Sablin MP; Le Tourneau C
Eur J Cancer; 2014 Feb; 50(3):638-48. PubMed ID: 24256808
[TBL] [Abstract][Full Text] [Related]
12. Dermatological side effects of current and upcoming targeted therapies in oncology.
Bonny M; Buyse V; Brochez L
Acta Clin Belg; 2011; 66(2):97-103. PubMed ID: 21630605
[TBL] [Abstract][Full Text] [Related]
13. Review of therapeutic drug monitoring of anticancer drugs part two--targeted therapies.
Widmer N; Bardin C; Chatelut E; Paci A; Beijnen J; Levêque D; Veal G; Astier A
Eur J Cancer; 2014 Aug; 50(12):2020-36. PubMed ID: 24928190
[TBL] [Abstract][Full Text] [Related]
14. Effect of inhibition of the FGFR-MAPK signaling pathway on the development of ocular toxicities.
van der Noll R; Leijen S; Neuteboom GH; Beijnen JH; Schellens JH
Cancer Treat Rev; 2013 Oct; 39(6):664-72. PubMed ID: 23434072
[TBL] [Abstract][Full Text] [Related]
15. Emerging toxicities in the treatment of non-small cell lung cancer: ocular disorders.
Agustoni F; Platania M; Vitali M; Zilembo N; Haspinger E; Sinno V; Gallucci R; de Braud F; Garassino MC
Cancer Treat Rev; 2014 Feb; 40(1):197-203. PubMed ID: 23850197
[TBL] [Abstract][Full Text] [Related]
16. Ophthalmic complications of targeted cancer therapy and recently recognized ophthalmic complications of traditional chemotherapy.
Kheir WJ; Sniegowski MC; El-Sawy T; Li A; Esmaeli B
Surv Ophthalmol; 2014; 59(5):493-502. PubMed ID: 25130892
[TBL] [Abstract][Full Text] [Related]
17. First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13).
Wicki A; Brown N; Xyrafas A; Bize V; Hawle H; Berardi S; Cmiljanović N; Cmiljanović V; Stumm M; Dimitrijević S; Herrmann R; Prêtre V; Ritschard R; Tzankov A; Hess V; Childs A; Hierro C; Rodon J; Hess D; Joerger M; von Moos R; Sessa C; Kristeleit R
Eur J Cancer; 2018 Jun; 96():6-16. PubMed ID: 29660598
[TBL] [Abstract][Full Text] [Related]
18. Preclinical approaches to assess potential kinase inhibitor-induced cardiac toxicity: Past, present and future.
Yang B; Papoian T
J Appl Toxicol; 2018 Jun; 38(6):790-800. PubMed ID: 29369373
[TBL] [Abstract][Full Text] [Related]
19. Ocular toxicities of MEK inhibitors and other targeted therapies.
Stjepanovic N; Velazquez-Martin JP; Bedard PL
Ann Oncol; 2016 Jun; 27(6):998-1005. PubMed ID: 26951625
[TBL] [Abstract][Full Text] [Related]
20. Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects.
Hartmann JT; Haap M; Kopp HG; Lipp HP
Curr Drug Metab; 2009 Jun; 10(5):470-81. PubMed ID: 19689244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]